Skip to content
November 27, 2022

Equity.Guru

Investment information for the new generation

NOVA.C

Biting the hand that feeds you Nova Mentis Life Sciences (NOVA.C) director Steven Feldman has some interesting thoughts around vaccines, and as a life sciences company, I think it’s…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Nova Mentis Life Science (NOVA.C) announced it has filed for orphan drug designation with the European Medicines Agency (EMA) for its propriety psilocybin drug to help treat patients with fragile…
Nova Mentis Life Science (NOVA.C) announced they have received Canadian approval for their North American autism clinical study. They received Institutional Review Board (IRB) approval in Canada on its…
When you write about the psychedelics industry, most of the people you speak with are corporate executives and most of what you read comes from PR personnel, so speaking…
Nova Mentis (NOVA.C) is on a mission to incorporate psychedelics in treating chronic inflammatory conditions like autism spectrum disorder (ASD), fragile X syndrome (FXS), epilepsy, traumatic brain injury, multiple…
Nova Mentis Life Science (NOVA.C) announced they will be organising a North American autism spectrum disorder (ASD) data bank to support the development of psilocybin-based compounds in the diagnosis…
Nova Mentis Life Science (NOVA.C) announced early indications of a rescue effect through psilocybin use on anxiety-like behaviours related to autism spectrum disorder (ASD).   The research involved studying…